PURPOSE: The goal of the current study was to explore visual function in virally suppressed HIV patients undergoing combined antiretroviral therapy (cART) by using pattern-reversal and motion-onset visual evoked potentials (VEPs). METHODS: The pattern-reversal and motion-onset VEPs were recorded in 20 adult HIV+ patients with a mean age of 38 years and CD4 cell counts ≥230 × 106 cells/L of blood. RESULTS: Nine out of 20 patients displayed VEP abnormalities. Pattern-reversal VEPs pathology was observed in 20% of subjects, and 45% HIV patients had impaired motion-onset VEPs. Five out of 16 neurologically asymptomatic HIV patients had prolonged motion-onset VEP latencies in both eyes. Four neurologically symptomatic patients displayed simultaneously abnormal motion-onset and pattern-reversal VEP latencies: monocular involvement was observed in two patients with Lyme and cytomegalovirus unilateral optic neuritis. Binocular involvement was noted in two patients with cognitive deficits. Correlation analysis between disease duration, CD4 cell count, HIV copies in plasma, MoCA and electrophysiological parameters did not show any significant relationships. CONCLUSIONS: The functional changes of the visual system in neurologically asymptomatic virally suppressed HIV patients displayed higher motion-onset VEP sensitivity than in standard pattern-reversal VEP examinations. This promising marker, however, has no significant association with clinical conditions. Further exploration is warranted.

Department of Epidemiology Faculty of Military Health Sciences University of Defence in Hradec Kralove Hradec Kralove Czech Republic

Department of Infectious Diseases Faculty Hospital in Hradec Kralove Hradec Kralove Czech Republic

Department of Pathological Physiology Faculty of Medicine in Hradec Kralove Charles University Simkova 870 500 03 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Vision Res. 2007 Jan;47(2):189-202 PubMed

J Neurovirol. 2009 Jul;15(4):324-33 PubMed

Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15647-52 PubMed

J Nucl Med. 1990 Oct;31(10):1601-7 PubMed

Acta Neuropathol. 2006 Oct;112(4):461-9 PubMed

Acta Neurol Belg. 1993;93(2):78-87 PubMed

AIDS Patient Care STDS. 1998 Mar;12(3):171-9 PubMed

Doc Ophthalmol. 1992;80(1):83-9 PubMed

J Neurol Sci. 1995 May;130(1):82-7 PubMed

Vision Res. 2006 Feb;46(4):536-44 PubMed

Doc Ophthalmol. 2004 Sep;109(2):169-75 PubMed

Neurol Clin. 2008 Aug;26(3):799-819, x PubMed

Br J Ophthalmol. 2000 May;84(5):551-3 PubMed

J Neurol. 2011 Jun;258(6):1066-75 PubMed

Am J Ophthalmol. 2008 Oct;146(4):579-88 PubMed

N Engl J Med. 1998 Mar 26;338(13):853-60 PubMed

Vision Res. 2012 Jun 1;62:9-16 PubMed

Neurology. 1996 Dec;47(6):1452-6 PubMed

EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb. 1989 Dec;20(4):257-66 PubMed

Neuroimage. 2006 May 15;31(1):86-108 PubMed

Graefes Arch Clin Exp Ophthalmol. 1995 Jul;233(7):387-98 PubMed

Electroencephalogr Clin Neurophysiol Suppl. 1990;41:355-69 PubMed

Br J Ophthalmol. 2004 Nov;88(11):1455-9 PubMed

Eur J Neurol. 2006 Mar;13(3):283-91 PubMed

J Clin Neurophysiol. 2012 Apr;29(2):174-80 PubMed

Top Antivir Med. 2011 Dec;19(5):175-80 PubMed

Neurophysiol Clin. 1992 Nov;22(5):369-84 PubMed

Doc Ophthalmol. 2010 Feb;120(1):111-9 PubMed

Trans Am Ophthalmol Soc. 1995;93:623-83 PubMed

Int J Clin Exp Med. 2014 Oct 15;7(10):3362-9 PubMed

Electroencephalogr Clin Neurophysiol. 1981 Nov;52(5):429-34 PubMed

J Virol. 2002 Aug;76(16):7923-31 PubMed

Cerebellum. 2011 Mar;10(1):32-42 PubMed

PLoS One. 2012;7(4):e35771 PubMed

PLoS One. 2012;7(12):e52895 PubMed

JAMA. 2002 Jul 10;288(2):222-35 PubMed

Brain Pathol. 1991 Apr;1(3):185-91 PubMed

Neuroimage. 2005 Feb 1;24(3):874-86 PubMed

J Clin Neurophysiol. 2006 Oct;23(5):416-20 PubMed

Visual evoked and event-related brain potentials in HIV-infected adults: a longitudinal study over 2.5 years